Skip to main content

Table 1 List of completed and ongoing clinical trials for the use of MSC in the treatment of ARDS

From: The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019

Trial ID

Title

Ref

Site

MSC source

No.of Pts

Route

Outcomes for MSC group

NCT01902082

Adipose-derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome

[111]

China, Zhejiang

AT

6 Control 6 Exp

I.V

No adverse reactions. Modest clinical improvements

NCT02097641

Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)

[99]

USA, multi-centre

BM

20 Control 40 Exp

I.V

No adverse reactions. Modest clinical improvements

ChiCTR-OCC-15006355

Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: A Hint for COVID-19 Treatment

[100]

China, Zhejiang

MB

44 Control 17 Exp

I.V

No adverse reactions. Reduction of Fatality rate

NCT02611609

A phase 1/2 study to assess MultiStem therapy in ARDS (MUST-ARDS)

[104]

USA, UK

BM-MAPC

9 Control 9 Exp 1 9 Exp 2 9 Exp 3

I.V

Preliminary: No adverse reactions. Reduction of Fatality rate. Reduction of ventilator assistance time

NCT02804945

Mesenchymal stem cells (MSCs) for treatment of ARDS (ARDS) in stem cell transplant patients

 

USA, Texas

BM

20 Exp

not stated

ongoing

NCT02215811

Treatment of severe acute respiratory distress syndrome with allogenic bone marrow derived MSCs

 

Sweden, Stockholm

BM

10 Exp

not stated

ongoing

NCT02444455

Human umbilical cord derived mesenchymal stem cell therapy in acute lung injury (UCMSC-ALI)

 

China, Beijing

UC

20 Exp

I.V

ongoing

  1. AT adipose Tissue, BM bone marrow, MAPC multi adult progenitor cell, MB menstrual blood, I.V. intra venous, Exp experimental